Global experts assembled in Kolkata to advance precision oncology at GCC - EZOS 2026
Times of India | 14 January 2026
KOLKATA: Leading scientists, clinicians, industry innovators, and policymakers from around the globe assembled in Kolkata for the recently concluded Conference of the Global Cancer Consortium 2026 and the 15th East Zonal Oncology Symposium (GCC-EZOS) 2026. The conference served as a premier global forum to advance personalised cancer diagnosis, treatment, and prevention through cutting-edge science and technology.
The international Conference on Personalised Therapy in the Era of Precision Oncology: A Glimpses into the Future brought global experts together to shape the future of cancer care. Specialists from within the country and abroad shared their expertise on the issue during the two day long programme.
Experts said that precision oncology is transforming cancer care by tailoring treatments based on individual genetic, molecular, and clinical profiles. GCC-EZOS 2026 highlighted the latest breakthroughs in genomics, biomarkers, artificial intelligence, immunotherapy, targeted therapeutics, surgical oncology, and translational research, bridging the gap between laboratory discovery and clinical application.
The 6th GCC-EZOS, in association with the Indian Association of Surgical Oncology, was hosted by Saroj Gupta Cancer Centre and Research Institute, Kolkata. Established in 1973 by the then young radiotherapist Dr Saroj Gupta, the institute began as a modest 25-bed shelter. The cancer specialty unit today is a fully equipped, 311-bed comprehensive cancer hospital.
"By bringing together global leaders in precision oncology, we aim to translate innovation into real-world impact for patients worldwide," said Dr Amab Gupta, Director, Saroj Gupta Cancer Centre and Research Institute, and Chairperson, Organising Committee.
Dr Vivek Rangnekar, Founding Chair, Global Cancer Consortium, said that this conference was designed to accelerate collaboration across disciplines and borders.
Scientific sessions and symposia on genomics-driven therapies, targeted therapies, AI in oncology and resistance mechanisms, and clinical and translational research presentations, including late-breaking studies, emerging technologies and therapeutics, and ethical and access-related challenges in precision medicine, along with pre-conference workshops on Cardio-Oncology and Cancer Genomics to sensitise the participants on the latest developments in these 2 areas, were part of the conference.